Key Stats for Gilead Science Stock
- Past-Week Performance: -1.6%
- 52-Week Range: $93.4 to $157.3
- Current Price: $150
What Happened?
Gilead Sciences (GILD) is no longer just an HIV franchise — its simultaneous commercial expansion across oncology, liver disease, and next-generation prevention is finally showing up in the numbers, with shares at $150.
On February 23, Gilead announced the $7.8B acquisition of Arcellx at a 79% premium, with Mizuho maintaining an Outperform rating and a $170 price target, arguing anito-cel carries comparable or better efficacy than Carvykti.
Biktarvy’s U.S. market share surpassed 52% while Yeztugo hit 90% payer coverage ahead of its one-year target, with full-year 2026 HIV guidance of 6% growth anchoring the base as anito-cel’s December 23 FDA decision approaches.
Beyond HIV, the Street’s conviction is broadening, with 17 buy ratings and a mean price target of $156.59 as of March 2, reflecting analysts rewarding execution across three therapeutic areas rather than one dominant franchise.
Chief Commercial and Corporate Affairs Officer Johanna Mercier stated on the Q4 earnings call that “we expect full year 2026 Yeztugo revenue of approximately $800 million compared to $150 million in 2025,” directly ahead of the company’s planned direct-to-consumer campaign launch.
With no major loss of exclusivity until 2036, up to 10 launches through 2027, and a TIKR mid-case price target of $194.88 implying 29.9% total return, Gilead is building the durable multi-product earnings base that justifies a structurally higher multiple over the next three to five years.
Wall Street’s Take on Gilead Sciences Stock
Gilead’s $7.8B Arcellx acquisition lands precisely as the company’s multi-front commercial expansion shifts from promise to execution, directly pulling forward oncology revenue that analysts hadn’t fully priced into forward estimates.
The fundamental engine supports that confidence, with FY 2025 revenue reaching $29.4B and normalized EPS surging 76.4% to $8.15, while consensus projects another 6.6% EPS growth to $8.68 in 2026.
Wall Street currently shows 17 buys, 5 outperforms, and only 7 holds as of March 2, with a mean price target of $156.59 implying roughly 4.4% upside from $150.03, reflecting analysts upgrading into strength rather than chasing momentum.
The target range spans $118 on the low end to $177 on the high end, where anito-cel’s December FDA decision determines the trajectory and a rejection or delay pushes shares toward the floor.
What Does the Valuation Model Say?
The TIKR valuation model sets a mid-case target of $194.88 against a current price of $150.03, projecting a total return of 29.9% over 4.8 years at a 5.6% annualized IRR.
The market appears to be underpricing Gilead’s margin recovery, as EBIT margins are forecast to expand to 47% in 2026 from a trough of 29.6% in 2024.
Thus, that recovery is not speculative — FY 2025 non-GAAP operating margin already reached 45%, confirming the structural cost discipline behind the forward estimate.
Management’s own guidance of $800M for Yeztugo in 2026 versus $150M in 2025 signals a franchise inflection that consensus has not yet fully rewarded in the multiple.
However, Veklury’s continued decline toward a $600M 2026 guide and any anito-cel approval setback could compress near-term EPS and delay the rerating the model assumes.
The December 23 FDA decision on anito-cel in fourth-line multiple myeloma is the single event that validates or stalls the entire oncology rerating thesis.
Gilead is undervalued at $150.03 given a $194.88 mid-case target and a pipeline inflection that the current multiple does not yet reflect; watch the anito-cel decision.
Should You Invest in Gilead Sciences, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up GILD stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Gilead Sciences, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze GILD stock on TIKR for Free →
